US FDA approves GE HealthCare's diagnostic drug for heart disease

(Reuters) - The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery disease, the company said on Friday. Flyrcado, which is a radioactive diagnostic drug for positron emission tomography (PET) myocardial perfusion imaging (MPI), will be available in some U.S. markets in early 2025 before being expanded. PET-MPI is a non-invasive